Inrebic Interactions
There are 561 drugs known to interact with Inrebic (fedratinib), along with 9 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 182 are major, 355 are moderate, and 24 are minor.
- View all 561 medications that may interact with Inrebic
- View Inrebic alcohol/food interactions (1)
- View Inrebic disease interactions (9)
Most frequently checked interactions
View interaction reports for Inrebic (fedratinib) and the medicines listed below.
- Actimmune (interferon gamma-1b)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Adzynma (apadamtase alfa, recombinant)
- Aimovig (erenumab)
- Alyftrek (deutivacaftor / tezacaftor / vanzacaftor)
- ambrisentan
- Amondys 45 (casimersen)
- Amvuttra (vutrisiran)
- Anusol-HC Suppositories (hydrocortisone topical)
- apremilast
- Aquaphor (emollients topical)
- Aspir 81 (aspirin)
- Atacand (candesartan)
- atorvastatin
- Attruby (acoramidis)
- Aubagio (teriflunomide)
- Augtyro (repotrectinib)
- Austedo XR (deutetrabenazine)
- azithromycin
- Bafiertam (monomethyl fumarate)
- Benadryl Allergy Sinus (diphenhydramine / pseudoephedrine)
- Benlysta (belimumab)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- Bimzelx (bimekizumab)
- Biotene Moisturizing Mouth Spray (saliva substitutes topical)
- Cymbalta (duloxetine)
- Eliquis (apixaban)
- levothyroxine
- metformin
Inrebic alcohol/food interactions
There is 1 alcohol/food interaction with Inrebic (fedratinib).
Inrebic disease interactions
There are 9 disease interactions with Inrebic (fedratinib) which include:
- severe hepatic impairment
- thiamine deficiency
- Fedratinib-gastrointestinal toxicity
- cardiovascular risk
- malignancy
- thrombosis
- renal impairment
- Fedratinib-cytopenias
- Fedratinib-pancreatitis
Report options
More about Inrebic (fedratinib)
- Inrebic consumer information
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Ojjaara
Ojjaara (momelotinib) may be used to treat adults with certain types of myelofibrosis (MF) who have ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Vonjo
Vonjo (pacritinib) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Pacritinib
Pacritinib (brand name Vonjo) is used to treat myelofibrosis with low platelet counts (cytopenic ...
Momelotinib
Momelotinib (brand name Ojjaara) may be used to treat adults with certain types of myelofibrosis ...
Ruxolitinib
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV) ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
